Vaishali Sanchorawala, MBBS
Professor
Boston University School of Medicine
Dept of Medicine
Hematology & Medical Oncology

MBBS, Seth G.S. Medical College




Expertise includes: AL amyloidosis - clinical trials, treatment; Stem cell transplantation; Myeloma.

Director
Boston University School of Medicine
Amyloidosis Center


Active Staff Hospital Privileges
Boston Medical Center
Medicine



2015 Research mentor award
2015 Schwartz Center for Compassionate Healthcare: Compassionate Caregiver Award
2011 Research Mentoring Award nomination
2011 Schwartz Center for Compassionate Healthcare: Compassionate Caregiver Award
2007-2009 Robert Dawson Evans Clinician Award
2000 IBMTR/ABMTR: Mortimer M. Bortin Award for best abstract


A Phase I Dose-Escalation Study of Carflizomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis
12/12/2013 - 12/12/2019 (PI)
Academic Myeloma Consortium


A phase 3 randomized, controlled, open-label, multicenter, safety and efficacy study of dexamethasone plus MLN9708 or physician's choice of treatment administered to patients with relapsed or refracto
09/28/2012 - 09/27/2019 (PI)
Millennium Pharmaceuticals, Inc.


Phase II study of the combination Bendamustine and Dexamethasone in patients with relapsed AL amyloidosis
09/04/2012 - 09/09/2019 (PI)
Trustees Of Columbia University In The City Of New York Cephalon, Inc.


A phase 1, open label, dose escalation study of intravenous administration of single agent NEOD001 in subjects with light chain (AL) amyloidosis
05/08/2013 - 05/07/2019 (PI)
Onclave Therapeutics Limited


Molecular Imaging of Primary Amyloid Cardiomyopathy
04/01/2017 - 03/31/2019 (Co-PI)
PI: Frederick L. Ruberg, MD
The Brigham and Women's Hospital, Inc. NIH NHLBI
5R01HL130563-02

An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients with Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further
04/01/2011 - 03/03/2019 (PI)
Millennium Pharmaceuticals, Inc.


A Phase I/II Trial of Pomalidomide and Dexamethasone for the treatment of patients with AL Amyloidosis
03/01/2012 - 02/28/2019 (PI)
Celgene Corporation


A Phase II Multi-Center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation with Post Transplant Maintenance for the Treatment of
01/06/2016 - 01/05/2019 (Co-PI)
PI: Robert W. Simms, MD
Fred Hutchinson Cancer Research Center Scleroderma Res Fdn


A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 PLus Lenalidomide and Dexamethasone versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients with Newly Diagno
12/03/2013 - 12/02/2015 (PI)
Millennium Pharmaceuticals, Inc.


Phase II trial of induction therapy with Bortezomib and Dexamethasone followed by high-dose melphalan and stem cell transplantation in patients with AL amyloidosis
04/01/2009 - 01/25/2014 (PI)
Millennium Pharmaceuticals, Inc.


Showing 10 of 14 results. Show All Results

54767414AMY3001
11/17/2017 - 11/17/2020 (PI)
Janssen Research and Development, LLC

Phase 1 Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL …
05/11/2015 - 05/31/2020 (PI)
Karmanos Cancer Center

NEOD001-CL002
09/24/2015 - 09/30/2019 (PI)
Prothena Therapeutics Limited

PRONTO - Protocol NEOD001-201
05/13/2016 - 05/31/2019 (PI)
Prothena Therapeutics Limited

DARA/JANSSEN PI Initiated
03/28/2017 - 03/28/2019 (PI)
Janssen Scientific Affairs LLC

Secondary Analysis of Amyloid Repository Data
09/15/2015 - 09/14/2017 (PI)
Prothena Therapeutics Limited



Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Qualls DA, Lewis GD, Sanchorawala V, Staron A. Orthotopic heart transplant rejection in association with immunomodulatory therapy for AL amyloidosis: a case series and review of the literature. Am J Transplant. 2019 Jun 17.View Related Profiles. PMID: 31207062.
     
  2. Sanchorawala V, Doros G, Shelton AC. Long term outcome of patients treated on clinical trials of immunomodulatory agents for the treatment of Immunoglobulin light chain (AL) amyloidosis: A pooled analysis. Am J Hematol. 2019 Jul; 94(7):E194-E196.View Related Profiles. PMID: 31020691.
     
  3. Ehman EC, El-Sady MS, Kijewski MF, Khor YM, Jacob S, Ruberg FL, Sanchorawala V, Landau H, Yee AJ, Bianchi G, Di Carli MF, Falk RH, Hyun H, Dorbala S. Early Detection of Multiorgan Light Chain (AL) Amyloidosis by Whole Body 18F-florbetapir PET/CT. J Nucl Med. 2019 Apr 06.View Related Profiles. PMID: 30954943; DOI: 10.2967/jnumed.118.221770;.
     
  4. Sanchorawala V. Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details. Blood Adv. 2019 Jan 22; 3(2):216-218. PMID: 30670538.
     
  5. Phull P, Sanchorawala V, Brauneis D, Sloan JM, Siddiqi OK, Quillen K, Sarosiek S. High-dose melphalan and autologous peripheral blood stem cell transplantation in patients with AL amyloidosis and cardiac defibrillators. Bone Marrow Transplant. 2019 Jan 21.View Related Profiles. PMID: 30664726.
     
  6. Gupta VK, Brauneis D, Shelton AC, Quillen K, Sarosiek S, Sloan JM, Sanchorawala V. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis. Biol Blood Marrow Transplant. 2019 May; 25(5):e169-e173.View Related Profiles. PMID: 30639823.
     
  7. Dennis M, Maoz A, Hughes D, Sanchorawala V, Sloan JM, Sarosiek S. Bortezomib ocular toxicities: Outcomes with ketotifen. Am J Hematol. 2019 Mar; 94(3):E80-E82.View Related Profiles. PMID: 30575098.
     
  8. Angel-Korman A, Stern L, Sarosiek S, Sloan JM, Doros G, Sanchorawala V, Havasi A. Long-term outcome of kidney transplantation in AL amyloidosis. Kidney Int. 2019 Feb; 95(2):405-411.View Related Profiles. PMID: 30580886.
     
  9. McCausland KL, Quock TP, Rizio AA, Bayliss MS, White MK, Guthrie SD, Sanchorawala V. Cardiac biomarkers and health-related quality of life in patients with light chain (AL) amyloidosis. Br J Haematol. 2019 Jun; 185(5):998-1001. PMID: 30467849.
     
  10. Merlini G, Dispenzieri A, Sanchorawala V, Schönland SO, Palladini G, Hawkins PN, Gertz MA. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018 Oct 25; 4(1):38. PMID: 30361521.
     
Showing 10 of 160 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 160 publications over 22 distinct years, with a maximum of 17 publications in 2018

YearPublications
19941
19982
19991
20014
20021
20035
20046
20055
200611
20076
20082
20097
201012
201112
201210
20135
201410
201510
201611
201715
201817
20197
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Amyloidosis [C18.452.845.500]
Stem cell transplantation
Clinical research
QoL

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Education Mentor
  • Project Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')


732 Harrison Ave
Boston MA 02118
Google Map


Sanchorawala's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department